Suppression of Rev3, the catalytic subunit of Pol zeta, sensitizes drug-resistant lung tumors to chemotherapy
Name
Doles-2010-Suppression of Rev3, the catalytic subunit of Pol zeta, sensitizes drug-resistant lung tumors to chemotherapy.pdf
Size
1.02 MB
Format
Adobe PDF
Checksum (MD5)
a61a2c587dea617577f28f5553b79768
Author(s)
Doles, Jason D.
Oliver, Trudy
Cameron, Eleanor Ruth
Hsu, Gerald
Jacks, Tyler E.
Walker, Graham C.
Hemann, Michael
Alternative Title
Suppression of Rev3, the catalytic subunit of Polζ, sensitizes drug-resistant lung tumors to chemotherapy
Date Issued
July 2011
Journal
Proceedings of the National Academy of Sciences of the United States of America
Publisher
National Academy of Sciences (U.S.)
Citation
Doles, J. et al. “Suppression of Rev3, the Catalytic Subunit of Pol , Sensitizes Drug-resistant Lung Tumors to Chemotherapy.” Proceedings of the National Academy of Sciences 107.48 (2010) : 20786-20791.
Version
Final published version
Abstract
Platinum-based chemotherapeutic drugs are front-line therapies for the treatment of non-small cell lung cancer. However, intrinsic drug resistance limits the clinical efficacy of these agents. Recent evidence suggests that loss of the translesion polymerase, Polζ [Pol zeta], can sensitize tumor cell lines to cisplatin, although the relevance of these findings to the treatment of chemoresistant tumors in vivo has remained unclear. Here, we describe a tumor transplantation approach that enables the rapid introduction of defined genetic lesions into a preclinical model of lung adenocarcinoma. Using this approach, we examined the effect of impaired translesion DNA synthesis on cisplatin response in aggressive late-stage lung cancers. In the presence of reduced levels of Rev3, an essential component of Polζ [Pol zeta], tumors exhibited pronounced sensitivity to cisplatin, leading to a significant extension in overall survival of treated recipient mice. Additionally, treated Rev3-deficient cells exhibited reduced cisplatin-induced mutation, a process that has been implicated in the induction of secondary malignancies following chemotherapy. Taken together, our data illustrate the potential of Rev3 inhibition as an adjuvant therapy for the treatment of chemoresistant malignancies, and highlight the utility of rapid transplantation methodologies for evaluating mechanisms of chemotherapeutic resistance in preclinical settings.
MIT Department
Massachusetts Institute of Technology. Department of Biology
Koch Institute for Integrative Cancer Research at MIT
Terms of Use
Article is made available in accordance with the publisher's policy and may be subject to US copyright law. Please refer to the publisher's site for terms of use.
Persistent DSpace Link
DOI of Published Version
https://doi.org/10.1073/pnas.1011409107
